ReviewPolish journal of radiology2026
In-bore MRI-guided prostate biopsy: current evidence, clinical applications, and future directions.
Review in Polish journal of radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is the second most common malignancy in men and a leading cause of cancer-related mortality worldwide. Accurate diagnosis is essential to guide therapeutic decision-making and to avoid the overtreatment of indolent tumors. In-bore magnetic resonance imaging-guided prostate biopsy (IB-MRGB) represents the most precise magnetic resonance imaging (MRI)-targeted technique for detecting clinically significant prostate cancer (csPCa). This review summarizes the current evidence, technical aspects, clinical relevance, and future perspectives of IB-MRGB. A comprehensive literature review was performed using PubMed, Scopus, and Embase, including studies that evaluated diagnostic performance, procedural workflow, and integration with focal therapies. IB-MRGB demonstrates high sensitivity (80-96%) and specificity (82-90%) for the detection of csPCa. It is particularly effective in biopsy-naïve patients with Prostate Imaging Reporting and Data System (PI-RADS) ≥ 3 lesions, in men with prior negative transrectal ultrasound-guided biopsies but persistent clinical suspicion, and in the context of active surveillance or focal therapy planning. Key advantages include superior lesion targeting and a reduction in the overdiagnosis of Gleason 3 + 3 tumors, whereas the main limitations are higher cost, longer procedure duration, and limited MRI availability. IB-MRGB aligns closely with the principles of precision oncology by enabling accurate diagnosis, risk stratification, and optimized treatment planning. Ongoing developments in artificial intelligence, radiomics, and MRI-guided interventions are expected to further enhance diagnostic efficiency and expand the clinical role of this technique.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.